BACKGROUND: This investigation aims to assess morbidity, mortality and postoperative outcomes of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer (REOC) with peritoneal metastases (PM). METHODS: Consecutive patients with radiographic evidence of REOC with PM were scheduled for CRS and HIPEC at the Comprehensive Cancer Center, University Hospital Tübingen, Germany. Clinical data were retrospectively analyzed. RESULTS: In total, 90 patients were analyzed. Complete cytoreduction and HIPEC could be performed in 69 % of patients. When categorizing patients with respect to the completeness of cytoreduction (CC-0/1 vs CC-2/3), there was no difference considering baseline demographic characteristics. Cumulative morbidity was 42 %. Morbidity rates did not statistically differ between CC-0/1 patients with HIPEC and CC-2/3 patients without HIPEC. No surgery-related and 90-day postoperative mortality was observed. In CC-0/1 patients, median overall survival was 35 months as opposed to 14 months in CC-2/3 patients. There was no difference in survival with respect to the peritoneal carcinomatosis index (PCI) as long as complete cytoreduction could be achieved. CONCLUSIONS: CRS and HIPEC can be performed with acceptable morbidity and low mortality in specialized centres. Our data do not suggest that HIPEC necessarily increases the risk of postoperative adverse events.
BACKGROUND: This investigation aims to assess morbidity, mortality and postoperative outcomes of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer (REOC) with peritoneal metastases (PM). METHODS: Consecutive patients with radiographic evidence of REOC with PM were scheduled for CRS and HIPEC at the Comprehensive Cancer Center, University Hospital Tübingen, Germany. Clinical data were retrospectively analyzed. RESULTS: In total, 90 patients were analyzed. Complete cytoreduction and HIPEC could be performed in 69 % of patients. When categorizing patients with respect to the completeness of cytoreduction (CC-0/1 vs CC-2/3), there was no difference considering baseline demographic characteristics. Cumulative morbidity was 42 %. Morbidity rates did not statistically differ between CC-0/1patients with HIPEC and CC-2/3patients without HIPEC. No surgery-related and 90-day postoperative mortality was observed. In CC-0/1patients, median overall survival was 35 months as opposed to 14 months in CC-2/3patients. There was no difference in survival with respect to the peritoneal carcinomatosis index (PCI) as long as complete cytoreduction could be achieved. CONCLUSIONS: CRS and HIPEC can be performed with acceptable morbidity and low mortality in specialized centres. Our data do not suggest that HIPEC necessarily increases the risk of postoperative adverse events.
Authors: F Raspagliesi; S Kusamura; J C Campos Torres; G A de Souza; A Ditto; F Zanaboni; R Younan; D Baratti; L Mariani; B Laterza; M Deraco Journal: Eur J Surg Oncol Date: 2006-04-18 Impact factor: 4.424
Authors: N Bakrin; J M Bereder; E Decullier; J M Classe; S Msika; G Lorimier; K Abboud; P Meeus; G Ferron; F Quenet; F Marchal; S Gouy; P Morice; C Pomel; M Pocard; F Guyon; J Porcheron; O Glehen Journal: Eur J Surg Oncol Date: 2013-10-17 Impact factor: 4.424
Authors: D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245
Authors: P Harter; M Hahmann; H J Lueck; M Poelcher; P Wimberger; O Ortmann; U Canzler; B Richter; U Wagner; A Hasenburg; A Burges; S Loibl; W Meier; J Huober; D Fink; W Schroeder; K Muenstedt; B Schmalfeldt; G Emons; A du Bois Journal: Ann Surg Oncol Date: 2009-02-19 Impact factor: 5.344
Authors: P Harter; A du Bois; S Mahner; J Pfisterer; O Ortmann; C Marth; D Fink; F Hilpert; U Wagner; J Sehouli Journal: Geburtshilfe Frauenheilkd Date: 2016-02 Impact factor: 2.915
Authors: Sebastian Blaj; Sebastian Nedelcut; Max Mayr; Hubert Leebmann; Daniel Leucuta; Gabriel Glockzin; Pompiliu Piso Journal: Langenbecks Arch Surg Date: 2019-07-27 Impact factor: 3.445
Authors: Lisa Überrück; Giorgi Nadiradze; Can Yurttas; Alfred Königsrainer; Ingmar Königsrainer; Philipp Horvath Journal: Ann Surg Oncol Date: 2020-11-09 Impact factor: 5.344